A simple plasma anticoagulant-exchange method to increase the recovery of factor VIII in therapeutic concentrates.
Donor blood, primarily anticoagulated by acid citrate dextrose formula A (ACD-A), was separated by means of the HemaScience Autopheresis C plasmapheresis device. The citrated plasma was collected directly into a solution of heparin and calcium chloride to achieve a final plasma-ionised calcium concentration of approximately 2 mM, and a heparin concentration of 1.0 IU/ml. Heparin at this concentration provided adequate anticoagulation, and did not result in insoluble cryoprecipitates. Three pairs of donor-matched 4-kg plasma pools (anticoagulant-exchanged variant and ACD-A-anticoagulated control) were constructed and subsequently fractionated to an intermediate stage. The mean recovery of factor VIII from 3 anticoagulant-exchanged pools (394 IU/kg) was 23% greater than the mean recovery from the matched control pools (319 IU/kg). This increased recovery was not achieved at the expense of specific activity.
Cumming
A M
AM
Department of Haematology, Royal Infirmary, Manchester, UK.
Wensley
R T
RT
Winkelman
L
L
Lane
R S
RS
D000925:Anticoagulants / Q000494:pharmacology*; D002118:Calcium / Q000032:analysis; D019343:Citric Acid; D005169:Factor VIII / Q000302:isolation & purification* / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products; D005344:Fibrinopeptide A / Q000032:analysis; D005345:Fibrinopeptide B / Q000032:analysis; D005947:Glucose / Q000031:analogs & derivatives* / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D010446:Peptide Fragments / Q000032:analysis; D010956:Plasmapheresis
D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; C033786:fibrinogen Bbeta (15-42); C002113:acid citrate dextrose; D005344:Fibrinopeptide A; D019343:Citric Acid; D005345:Fibrinopeptide B; D005169:Factor VIII; D006493:Heparin; D005947:Glucose; D002118:Calcium